Open an account

Codexis

CDXS · NASDAQ

$1.23−$0.09 (−6.82%)TodayMarket closed ·
Prev close $1.32

About CDXS

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 146 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The firm utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The firm also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Employees
146
Headquarters
Redwood City, California
Listed
Apr 22, 2010
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
codexis.com

CDXS key statistics

Market cap
134.69M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
796.11K
Volume
1.21M
Open price
$1.32
High today
$1.35
Low today
$1.21
52 Week high
$2.98
52 Week low
$0.96

Codexis (CDXS) at a glance

As of Oct 20, 2026, Codexis (CDXS) shares are priced at $1.23, giving the company a market cap of 134.69M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.21 and $1.35. The current price is 1.7% above the day's low and 8.9% below its high.

Volume so far is 1.21M shares, above the average of 796.11K shares a day.

Over the past year Codexis has ranged from $0.96 to $2.98, and now sits 13% of the way up that range.

Codexis met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.13 per share against an estimate of -$0.1408.

The average analyst price target is $6.27, 409.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $6.27
Low
$2.02
Now
$1.23
High
$11.55

CDXS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 102.4% on average.

  1. Q3 FY24: reported -$0.29 per share against an estimate of -$0.2435
  2. Q4 FY24: reported -$0.13 per share against an estimate of -$0.037
  3. Q1 FY25: reported -$0.25 per share against an estimate of -$0.2419
  4. Q2 FY25: reported -$0.16 per share against an estimate of -$0.1923
  5. Q3 FY25: reported -$0.22 per share against an estimate of -$0.1515
  6. Q4 FY25: reported $0.11 per share against an estimate of -$0.0428
  7. Q1 FY26: reported -$0.10 per share against an estimate of -$0.1394
  8. Q2 FY26: reported -$0.13 per share against an estimate of -$0.1408

CDXS news

  • Avi Kapoor

    Crude Oil Down Over 4%; Verizon Raises Earnings Forecast

  • Avi Kapoor

    US Stocks Mixed; American Express Shares Fall Following Q2 Results

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Tanya Rawat

    Why Codexis Stock Is Falling After Hours Today

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Crude Oil Surges Over 8%; Dollar General Shares Fall After Q4 Results

  • Avi Kapoor

    Dow Tumbles Over 1%; US Weekly Jobless Claims Fall

Similar companies

Companies in the same industry as Codexis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.